Canopy Biosciences
Now part of Bruker Spatial Biology, Canopy Biosciences was a biotechnology company that specialized in providing access to multiomics technologies for spatial biology and gene expression profiling. Established in St. Louis, Missouri, Canopy Biosciences developed a spatial proteomics instrument and also offered a range of services to support oncology and immunology research. Services included spatial transcriptomics, gene expression, spatial proteomics, and data analysis. History2016 (foundation)Canopy Biosciences was founded in 2016 with the goal of commercializing academic technologies and offering access (as a service provider) to multiomics tools for gene expression analysis.[1] The company was established by BioGenerator, an investment arm of BioSTL, which provides startup capital and support to bioscience companies. 2019 (strategic acquisitions)In 2019, Canopy Biosciences raised a Series B round led by Ampersand Capital Partners, which was used to acquire Zellkraftwerk GmbH and CORE Diagnostics.[2] The acquisition of Zellkraftwerk GmbH brought ChipCytometry technology and the ZellScannerONE instrument to Canopy, enhancing its spatial immunophenotyping capabilities.[3] CORE Diagnostics, a provider of CLIA-certified laboratory services, expanded Canopy’s offerings to include clinical diagnostics, histology, IHC, and FISH (fluorescence in situ hybridization).[4] 2020 (acquisition by Bruker)In 2020, Canopy Biosciences was acquired by Bruker Corporation, a manufacturer of scientific instruments. This acquisition allowed Canopy to leverage Bruker's global infrastructure and expertise in product design and engineering. The financial terms of the deal were not disclosed.[5] 2022–2024 (recent developments)In 2022, Canopy Biosciences launched the CellScape Precise Spatial Multiplexing platform, integrating fluidics for automation and offering high-resolution imaging for multiplex immunofluorescence.[6] In 2023, Canopy partnered with Enable Medicine to integrate advanced spatial analysis tools into the CellScape platform.[7] In 2024, Bruker Corporation acquired the assets from NanoString Technologies, expanding its spatial biology capabilities.[8] The assets from the NanoString acquisition were merged with Canopy Biosciences and another Bruker-owned subsidiary, Bruker Spatial Genomics, to form a new division, Bruker Spatial Biology.[9] Technologies
Services
References
|
Portal di Ensiklopedia Dunia